Business
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
1H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) Planned for Early Q2 2026Initial Proof-of-Concept for ALLO-329, the Dual CD19/CD70 AlloCAR T Leveraging the Dagger® Technology to Reduce or Eliminate Lymphodepletion in the Treatment of Autoimmune Dise
About this update from Allogene Therapeutics, Inc.
[{"type":"image","alt":"Allogene Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Allogene Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":126,"url":"https://media.zenfs.com/en/globenewswire.com/e1380caace874bf039771959c9835030"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QCsYA1reL6jmKogB1ZpqzA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e1380caace874bf039771959c9835030","width":300,"height":126}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"1H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease","length":111,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Interim Futility Analysis of MRD Clearance from the Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line (1L) Consolidation Large B-Cell Lymphoma (LBCL) Planned for Early Q2 2026","length":212,"tagName":"p"}]},{"val":[{"type":"text","content":"Initial Proof-of-Concept for ALLO-329, the Dual CD19/CD70 AlloCAR T Leveraging the Dagger® Technology to Reduce or Eliminate Lymphodepletion in the Treatment of Autoimmune Diseases, Slated by the End of 1H 2026","length":210,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":422,"olType":false}]},{"val":[{"type":"text","content":"Cash Runway Continues into 2H 2027","length":34,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":567,"olType":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today outlined 2026 as a program-defining year for allogeneic CAR T, with multiple first-half clinical readouts expected to test, and potentially validate, whether off-the-shelf CAR T can be delivered at biologic-like scale, in real-world settings, across oncology and autoimmune disease.","length":537,"tagName":"p"},{"type":"text","content":"After nearly eight years of platform development and treatment of more than 200 patients across six clinical studies, Allogene has built an off-the-shelf CAR T platform designed to deliver clinical utility, broad patient ac...